文献速递临床免疫分子诊断

Elecsys抗SARS-CoV-2刺突蛋白受体结合域抗体半定量检测在cobas e602分析仪上的分析与临床评估

Analytical and Clinical Evaluation of the Semiquantitative Elecsys Anti-SARS-CoV-2 Spike Protein Receptor Binding Domain Antibody Assay on the Roche cobas e602 Analyzer.
PubMed 文献 · Am J Clin Pathol · 2022-01-01

该研究在Roche cobas e602分析仪上对半定量Elecsys抗SARS-CoV-2刺突蛋白抗体(S-Ab)检测进行性能评估,检测总IgG、IgM和IgA。结果显示该方法精密度好、线性范围0.4-250 U/mL、无显著交叉反应或干扰,与N-Ab检测和侧流装置定性符合率>90%,与ELISA相关,对PCR阳性后≥14天样本灵敏度与特异性均为100%。

要点

  • S-Ab检测精密度好,线性范围0.4-250 U/mL,不受血红蛋白、胆红素、甘油三酯和生物素干扰。
  • 与N-Ab检测和侧流装置定性符合率>90%,读数与ELISA相关,ELISA与病毒中和试验强相关。
  • 对PCR阳性后≥14天COVID-19患者样本灵敏度与特异性均为100%。

核心结论

  • Elecsys S-Ab检测是用于定性及半定量检测SARS-CoV-2感染或刺突编码mRNA COVID-19疫苗接种后血清阳性的稳健临床检测方法。

研究设计与样本

  • 研究在Roche cobas e602分析仪上评估半定量Elecsys S-Ab检测,该检测为一步双抗原夹心电化学发光免疫分析法,检测血清或血浆中针对SARS-CoV-2刺突蛋白受体结合域的总IgG、IgM和IgA抗体。
  • 评估内容包括精密度、线性、干扰(血红蛋白、胆红素、甘油三酯和生物素)、交叉反应和临床性能,并与定性Elecsys抗核衣壳(N-Ab)免疫分析、定性检测S-Ab和N-Ab的侧流装置以及抗刺突酶联免疫吸附试验(ELISA)进行比较。

主要发现

  • S-Ab检测精密度好,在0.4至250 U/mL范围内呈线性,不受显著交叉反应或干扰影响。
  • S-Ab检测与N-Ab检测和侧流装置定性符合率大于90%。
  • S-Ab检测读数与ELISA相关,而ELISA与SARS-CoV-2病毒中和试验强相关。
  • 对PCR阳性后14天或更长时间获得的COVID-19患者样本,S-Ab检测显示100%灵敏度和100%特异性。

关键数值与推荐

  • 线性范围为0.4至250 U/mL。
  • 与N-Ab检测和侧流装置定性符合率大于90%。
  • 对PCR阳性后≥14天COVID-19患者样本,灵敏度和特异性均为100%。

临床怎么用

  • 该检测可用于定性和半定量评估SARS-CoV-2感染或刺突编码mRNA COVID-19疫苗接种后的血清阳性状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To analytically and clinically evaluate the semiquantitative Elecsys anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody (S-Ab) assay on the Roche cobas e602 analyzer. METHODS: The S-Ab assay is a 1-step, double-antigen sandwich electrochemiluminescent immunoassay that semiquantitatively measures total IgG, IgM, and IgA antibodies specific for the receptor binding domain of SARS-CoV-2 spike protein in serum or plasma. The S-Ab assay was evaluated for precision, linearity, interference (by hemoglobin, bilirubin, triglycerides, and biotin), cross-reactivity, and clinical performance, and was compared to the qualitative Elecsys anti-nucleocapsid (N-Ab) immunoassay, a lateral flow device that qualitatively detects S-Ab and N-Ab, and an anti-spike enzyme-linked immunosorbent assay (ELISA). RESULTS: S-Ab assay is precise, exhibits linearity from 0.4 to 250 U/mL, is unaffected by significant cross-reactivity or interferences, and qualitatively demonstrates greater than 90% concordance with N-Ab assay and lateral flow device. Readouts of S-Ab assay correlate with ELISA, which in turn correlates strongly with SARS-CoV-2 virus neutralization assay, and exhibit 100% sensitivity and specificity for COVID-19 patient samples obtained at or more than 14 days after PCR positivity. CONCLUSIONS: The S-Ab assay is a robust clinical test for qualitative and semiquantitative detection of seropositivity following SARS-CoV-2 infection or spike-encoding mRNA COVID-19 vaccination.

来源:Am J Clin Pathol,查看原文。版权归原作者所有。

引用

  1. Chan CW, Yi X, Lenza M, et al. Analytical and Clinical Evaluation of the Semiquantitative Elecsys Anti-SARS-CoV-2 Spike Protein Receptor Binding Domain Antibody Assay on the Roche cobas e602 Analyzer. Am J Clin Pathol. 2022. PMID: 34463315. doi:10.1093/ajcp/aqab092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。